Oculis Holding (OCS) said Monday a phase 2 trial evaluating OCS-05 in patients with acute optic neuritis met the primary endpoint of safety and achieved statistical significance on several efficacy-based secondary endpoints.
Acute optic neuritis is a condition characterized by inflammation of the optic nerve that can results in permanent visual impairment.
The trial highlighted "neuroprotective structural benefit and the ability to improve visual function in patients suffering from acute optic neuritis," the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.